Beximco Pharmaceuticals (LON:BXP) Hits New 12-Month High - Time to Buy?

Key Points

• Beximco Pharmaceuticals Limited reached a new 52-week high price of GBX 43 ($0.57) during trading, indicating a 15.4% increase from its previous closing price of GBX 39 ($0.52).
• The company has a market capitalization of £30.68 billion, a PE ratio of 4.83, and a debt-to-equity ratio of 12.47, reflecting strong financial metrics.
• Beximco Pharma, established in 1976, is a leading manufacturer and exporter of medicines in Bangladesh, transitioning from importing to manufacturing its own products over the decades.

Beximco Pharmaceuticals Limited (LON:BXP - )'s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as GBX 43 ($0.57) and last traded at GBX 43 ($0.57), with a volume of 126945 shares trading hands. The stock had previously closed at GBX 39 ($0.52).

Beximco Pharmaceuticals Trading Up 15.4%

The company has a debt-to-equity ratio of 12.47, a current ratio of 2.13 and a quick ratio of 0.37. The firm has a market capitalization of £30.68 billion, a PE ratio of 4.83 and a beta of 0.61. The business's 50-day moving average price is GBX 37.94 and its 200-day moving average price is GBX 37.86.

Beximco Pharmaceuticals Company Profile

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.